Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.

By C. Roehrborn, Peter Boyle, J. Nickel, K. Hoefner, G. Andriole. Urology, 2002

699 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. (2013, background): “A long-term trial with dutasteride in symptomatic men with prostate volumes >30 ml and increased risk for disease progression showed that dutasteride reduced LUTS in these patients at least as much or even more effectively than the a1-blocker tamsulosin [17,18,32].”
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. (2010, result): “At month 48, the adjusted mean percentage decrease in total prostate volume with combination therapy and dutasteride was similar to what was observed at month 24 [10] and also to what has been previously reported for dutasteride [13,14].”